<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>Table 1</label>
 <caption>
  <p>Summary of the mechanisms of coumarins as antitumor drugs.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">Coumarins</th>
    <th valign="top" align="center" rowspan="1" colspan="1">Test type</th>
    <th valign="top" align="center" rowspan="1" colspan="1">Effective concentration</th>
    <th valign="top" align="center" rowspan="1" colspan="1">Mechanisms</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Compound 8i (
     <xref rid="B5" ref-type="bibr">5</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">CA IX: 45.5 nM CA XII: 596.6 nM</td>
    <td valign="top" rowspan="6" align="left" colspan="1">selective inhibitory activities to CA IX and CA XII</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Compound 5p and 5n (
     <xref rid="B6" ref-type="bibr">6</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">CA IX: 144.6 nM and 71.5 nM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">1-aryl and 2-aryl-substituted Coumarin derivatives (
     <xref rid="B7" ref-type="bibr">7</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">CA IX: 9.6 nM
     <break/>CA XII: 5.8 nM and 25.2 nM
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">4-sulfamoylphenyl/sulfocoumarin benzamides (
     <xref rid="B8" ref-type="bibr">8</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">CA IX: 99.4–4092.5 nM
     <break/>CA XII: 30.6–7461.5 nM
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">dihydroartemisinin-coumarin hybrids (
     <xref rid="B9" ref-type="bibr">9</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">CA IX: 0.17 μM
     <break/>CA XII: 0.17 μM
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">2-thioxocoumarine derivative 15 and 16 (
     <xref rid="B10" ref-type="bibr">10</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">0.004–0.027 μM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Compound 5h and 5m (
     <xref rid="B15" ref-type="bibr">15</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">18.1–32.6 μM and 29.3-42.1 μM</td>
    <td valign="top" rowspan="6" align="left" colspan="1">inhibition of the expression or phosphorylation of PI3K, Akt, and mTOR</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">5-methoxypsoralen (
     <xref rid="B16" ref-type="bibr">16</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">75 μM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Isofraxidin (
     <xref rid="B17" ref-type="bibr">17</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">40 μM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">TCHD (
     <xref rid="B18" ref-type="bibr">18</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">75–125 μg/ml</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Imperatorin (
     <xref rid="B19" ref-type="bibr">19</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">75 μM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">3-benzyl coumarin deca-B-ring derivative (
     <xref rid="B20" ref-type="bibr">20</xref>)
     <break/>Ferulin C (
     <xref rid="B21" ref-type="bibr">21</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">53 nM
     <break/>
     <break/>20 μM
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Ferulin C (
     <xref rid="B21" ref-type="bibr">21</xref>)
     <break/>Xanthyoxylin and 6, 7, 8-trimethoxyl-coumarin (
     <xref rid="B24" ref-type="bibr">24</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">20 μM
     <break/>0.1 μg/ml
    </td>
    <td valign="top" rowspan="6" align="left" colspan="1">up-regulate the expression of pro-apoptotic proteins, and down-regulate the expression of anti-apoptotic proteins</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Isofraxidin (
     <xref rid="B17" ref-type="bibr">17</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">10 μg/ml</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">TCHD (
     <xref rid="B18" ref-type="bibr">18</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">75–125 μg/ml</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">8-methoxy coumarins hybridize with three bioactive moieties (
     <xref rid="B25" ref-type="bibr">25</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">0.65–0.93 μM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">PulchrinA (
     <xref rid="B26" ref-type="bibr">26</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">22 μM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">A nitro-coumarin derivate (
     <xref rid="B27" ref-type="bibr">27</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">40 μM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Esculetin (
     <xref rid="B28" ref-type="bibr">28</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">100 μM</td>
    <td valign="top" rowspan="3" align="left" colspan="1">up-regulate the expression of pro-apoptotic proteins, and down-regulate the expression of anti-apoptotic proteins;
     <break/>induce the generation and accumulation of ROS overly or decrease the intracellular ROS level
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Compound 5f (
     <xref rid="B29" ref-type="bibr">29</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">26.43 μM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">PMMB232 (
     <xref rid="B30" ref-type="bibr">30</xref>)
     <break/>Esculetin (
     <xref rid="B38" ref-type="bibr">38</xref>)
     <break/>Ligand-L (
     <xref rid="B39" ref-type="bibr">39</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
     <break/>
     <italic>In vitro</italic>
     <break/>
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">3.25±0.35 μM
     <break/>10 μM
     <break/>250 mg/kg
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Mansorin-II; (
     <xref rid="B31" ref-type="bibr">31</xref>)
     <break/>Coumarin derivatives (
     <xref rid="B32" ref-type="bibr">32</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">0.74–36 µM</td>
    <td valign="top" rowspan="2" align="left" colspan="1">interfer with the efflux activity of P-gp or MRP2</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Conferdione and Samarcand (
     <xref rid="B33" ref-type="bibr">33</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">22.75 ± 3.88 μM and &gt;50 µM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Ferulin C (
     <xref rid="B21" ref-type="bibr">21</xref>)
     <break/>Compound 65 (
     <xref rid="B34" ref-type="bibr">34</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
     <break/>
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">25 mg/kg
     <break/>3.5–31.9 nM
    </td>
    <td valign="top" rowspan="2" align="left" colspan="1">target colchicine binding sites, inhibit microtubules polymerization</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">4-substituted coumarin H6 (
     <xref rid="B35" ref-type="bibr">35</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">7-47 nM</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">TCH-5C (
     <xref rid="B40" ref-type="bibr">40</xref>)
     <break/>7-isopentenyloxycoumarin (
     <xref rid="B41" ref-type="bibr">41</xref>)
     <break/>Compound 4a (
     <xref rid="B42" ref-type="bibr">42</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
     <break/>
     <italic>In vitro</italic>
     <break/>
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">3 mg/kg
     <break/>50 mg/kg
     <break/>1.24–8.68 µM
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">reduce VEGF-induced angiogenesis</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Esculetin (
     <xref rid="B38" ref-type="bibr">38</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">10 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">inhibit STAT3 phosphorylation</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Esculetin (
     <xref rid="B28" ref-type="bibr">28</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">100 µM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">increase the amount of anti-tumor factor Nrf2</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Scopoletin (
     <xref rid="B46" ref-type="bibr">46</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">0.88 mM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">inhibitory effect on NQO1</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Psoralidin (
     <xref rid="B47" ref-type="bibr">47</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">25 mg/kg</td>
    <td valign="top" align="left" rowspan="1" colspan="1">inhibit Notch-1 in breast cancer cells</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Compound 4a (
     <xref rid="B48" ref-type="bibr">48</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">0.09 ± 0.01µM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">inhibition of the expression of MCT1</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">PMMB232 (
     <xref rid="B30" ref-type="bibr">30</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">4µM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">promote HIF-1α degradation;
     <break/>up-regulate the expression of E-cadherin
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Coumarin derivatives based on HMCB (
     <xref rid="B49" ref-type="bibr">49</xref>)
     <break/>compound 2c (
     <xref rid="B50" ref-type="bibr">50</xref>)
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">
     <italic>In vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">4.1 ± 0.3nM and 3.4 ± 0.1nM
     <break/>
     <break/>0.44 mM
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">inhibition for AKR1B10</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
